Pharmafile Logo

Peter Impey

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

- PMLiVE

Does disruptive thinking leave you feeling threatened?

What it takes to change healthcare

Synergy Vision bolsters UK presence

Opens new office in West Sussex

- PMLiVE

Axovant poaches Allergan’s and Teva’s chief medical and science officers

Gavin Corcoran and Michael Hayden join the biopharma

Sue Mahony to retire as president of Lilly Oncology

She will continue in her position until August 31

Why patient education isn’t simple - 1

Why patient education isn’t simple

The terms patient education, patient activation and patient engagement are increasingly popular as healthcare becomes more patient-centric. In this article, Clare Mariconda discusses how the concepts link together and shares...

Cuttsy + Cuttsy

- PMLiVE

Open minds for open innovation

When it comes to problem-solving, getting an outsider’s perspective can really add value. Addressing an issue from a different angle or injecting new expertise ultimately leads to a more robust...

- PMLiVE

Biotech: it’s a people business

Nancy Hunter is the Marketing Director at a cutting-edge pharmaceutical company. Here she explains how a sharp focus on patients’ needs is driving a new operating model for marketing first-in-class...

Blue Latitude Health

- PMLiVE

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

All the latest from the frontline of pharma, biotech and healthcare

- PMLiVE

ASCO data back up Merck & Co’s dominance in lung cancer

Keytruda improved survival of previously-untreated NSCLC patients by four-eight months, according to data

Bristol-Myers Squibb (BMS) building

BMS presses go on Nektar combo pivotal trials, despite data debate

The data isn’t mature enough to give an accurate ORR reading, says companies

- PMLiVE

Changes to look out for in Medical Devices Regulations

Will digital lead to a greater compliance burden?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links